ReviewJournal of thoracic disease2024
Hepatic hydrothorax.
Review in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 13 citations in OpenAlex.
- [Thoracoscopic diaphragmatic plication technique in a patient with refractory hepatic hydrothorax].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Determinants of Early Renal Function Recovery After TIPS in Patients With Portal Hypertension.The Kaohsiung journal of medical sciences · 2026Article
- Dynamic right diaphragmatic herniation revealed by point-of-care ultrasound in hepatic hydrothorax.The ultrasound journal · 2026Article
- A Rare Presentation of Right-Sided Pleural Effusion in Decompensated Chronic Liver Disease Secondary to Hepatitis C Infection: A Case Report.Clinical case reports · 2026Article
- Taking advantage of the high sensitivity of Long Axial Field-Of-View (LAFOV) PET/CT systems: a novel method for abdominothoracic lymphatic drainage visualization using [European journal of nuclear medicine and molecular imaging · 2026Article
- MELD 3.0: Exploring and expanding its utility beyond transplantation.Hepatology forum · 2026Review
- Symptomatic pleural effusion in adult liver transplant candidates: prevalence, disease severity and post-transplant mortality.BMC pulmonary medicine · 2025Article
- Hepatic Hydrothorax: A Review.Current hepatology reports · 2025Article
- Hepatic hydrothorax in the absence of ascites with mixed bacterial and fungal infection: a case report.BMC infectious diseases · 2025Article
- Porous Diaphragm Syndrome: A Literature Review.Cureus · 2025Review
- The Impact of Hepatic Hydrothorax on the Outcome of Liver Cirrhosis: A Comparative Study.Journal of clinical medicine · 2025Article
- Application of methylene blue injection staining in the diagnosis of hepatic pleural effusion in patients with cirrhosis-a case report and literature review.AME case reports · 2025Article
- Octreotide infusion as a treatment for hepatic hydrothorax in a hospital-at-home program: case report from Mayo Clinic.Therapeutic advances in gastroenterology · 2025Article
- Article
- Hepatic Hydrothorax: A Comprehensive Approach to Diagnosis and Management.GE Portuguese journal of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic hydrothorax (HH) refers to the presence of a pleural effusion that develops in the context of underlying liver cirrhosis and portal hypertension. It carries a high risk of morbidity and mortality, with a median survival of 8-12 months. Diagnosis is usually confirmed by pleural aspiration, demonstrating typical features of a transudative effusion in the absence of co-existent cardio-pulmonary or renal pathology. The clinical presentation is quite variable, with some patients remaining relatively asymptomatic in the presence of small or incidental effusions, while others present with frank respiratory failure requiring pleural intervention. The development of spontaneous bacterial empyema (SBEM) is a significant and not infrequent complication, requiring prompt recognition and treatment. While the mainstay of management is focused on optimising fluid balance through dietary salt restriction and diuretic therapy, liver transplantation remains the definitive treatment option. As such, it is crucial to adopt a multi-disciplinary approach-involving pulmonologists, hepatologists, dieticians, and palliative care physicians-in order to optimise care for this often complex group of patients. This review will discuss the basic pathophysiology of HH, its clinical presentation and diagnosis, as well as the approach to management of HH in clinical practice, focussing on both interventional and non-interventional treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.